- Home
- News
- Treatment & Care
- HIV Worldwide
- Living with HIV
- Preventing HIV
- Organisations
- HIV Basics
- About Us
- The need for a vaccine
- What a vaccine can do
- Preventive trials: Phase I, II, III
- Logistical issues in Phase III trials
- Mobilising support worldwide
- United States of America
- Thailand
- Brazil
- African research
- European research
- The International AIDS Vaccine Initiative
- The development of candidate vaccines
- Vaxgen's trials
- Other companies
- Ethical issues in trial design
- UNAIDS' guidelines
- Trials that 'fail'
- Who would European trial volunteers be?
- Mother-to-child transmission
- Therapeutic vaccines
- Antiretroviral treatment
- Implications for people with HIV
- Implications for HIV-negative people
- Securing global access
- An evolving programme
Ethical issues in trial design
The general ethical principles that govern all clinical research apply to vaccine trials, and there are a number of international statements on medical ethics that apply. It is fundamental that participation in trials must be voluntary and based on individual informed consent.
The principal difference between preventive vaccine trials and HIV therapeutic trials is that because participants might otherwise have a normal life expectancy and a low level of disability, the level of potentially acceptable risk is much lower.
In the case of HIV preventive vaccines, much of the discussion of ethics of trials has been driven by perceived and actual disparities of power between those at high risk of HIV and those carrying out the research, and between Western countries and multinational companies and communities in developing countries. There is an obvious danger of exploitation, if benefits and risks from research are not evenly shared. There is also a danger that if governments and international agencies are over-protective, the effort will be stalled.
